Cytosorbents Corporation (FRA:HQE1)

Market Cap	19.42M -60.3%
Revenue (ttm)	32.58M +3.1%
Net Income	-15.94M
EPS	-0.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2800
Previous Close	0.2740
Day's Range	0.2800 - 0.2800
52-Week Range	0.2080 - 0.8270
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammator...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1997
• Employees: 129
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HQE1

Financial Performance

In 2025, Cytosorbents's revenue was $37.06 million, an increase of 4.12% compared to the previous year's $35.60 million. Losses were -$8.20 million, -60.43% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error